Editorial, 4/03 By Dr. Larry Weisenthal
Regarding Ovarian Cancer Assays Showing Results Which Do Not Support Treatment with "Standard" Taxol/Platinum as First Line Therapy
History of Randomized Clinical Trials in Ovarian Cancer: Pre-Taxol Era
For many years (from the early 60s to late 70s), the "standard" ovarian cancer chemotherapy was single agent melphalan (or chemotherapy with a related "alkylating agent," such as cyclophosphamide).
These "alkylators" were inexpensive and usually well tolerated oral drugs. In the late 70s, the NCI reported the results of a randomized clinical trial in the New England Journal of Medicine in which a complex and toxic combination ("HEXA-CAF") ostensibly produced superior results, compared to single agent melphalan.
But this study was not confirmed. By the early 80s, some data appeared initially to support the concept that cisplatin-based combinations might produce superior outcomes.
Read the entire article here:
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.